SuperworthCG Oncology price to book ratio CGON
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 5.3×
- 2-year median
- 4.4×
- Against its 2-year history
- 72nd
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 1.8× to 8.2×
- Peer median
- 5.6×
CG Oncology's price to book ratio is 5.3× as of Oct 23, 2026.
That is above its 2-year median of 4.4×, higher than on 72% of days in the last 2 years.
Over that time it ranged from 1.8× in Apr 2025 to 8.2× in Apr 2026.
The median for 10 biotech stocks of a similar size is 5.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.3× | 4.3× | 8.2× |
| 2025 | 4.7× | 1.8× | 5.3× |
| 2024 | 3.8× | 3.3× | 4.9× |
Against its peers
Companies in Biotechnology nearest CG Oncology's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| CGONCG Oncology | 5.3× |
| KRYSKrystal Biotech | 6.8× |
| RGENRepligen | 4.7× |
| TECHBIO-TECHNE | 5.4× |
| ADMAAdma Biologics | 5.9× |
| VCELVericel | 5.9× |
| HALOHalozyme Therapeutics | 99.3× |
| NBIXNeurocrine Biosciences | 3.9× |
| EXELExelixis | 8.7× |
| INCYIncyte | 3.7× |
| UTHRUnited Therapeutics | 3.9× |
| Peer median | 5.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on CG Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.